Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Table 1 Autologus hemapoietic stem cells transplantation studies in Crohn's disease

Ref.	Patients (n)	Follow up(mo)	Deaths	Remission(number of patients, time of evaluation in months)	Recurrence(number of patients or %, time of evaluation in months)
Oyama et al[24]	12	18.5 mo (7-37)	No	Clinical 11 (12 mo)	1% (18.5 mo)
Burt et al[25]	24	60 mo	1 not related	Clinical 24 (6-12 mo)	9% (12 mo)
					37% (24 mo)
					43% (36 mo)
					61% (48 mo)
					81% (60 mo)
Cassinotti et al[26]	10	56 mo (23-68)	No	Clinical 10 (3 mo) Endoscopic 5 (3 mo)	20% (12 mo)
					50% (24 mo)
					60% (36 mo)
					70% (48 mo)
					70% (60 mo)
Hasselblatt et al[27]	12	37 mo (IQR 6-123)	No	Clinical 4/8 (6 mo) Endoscopic 5/9 (9.1 mo) 3/9 mild disease	7% (10.9 mo)
Hawkey[28]	Data from 30 out of 45 patients 16 mobilisation + HCST (A) 16 mobilisation (B)		1 death after HCST	NA A: CDAI fell 162 (IQR 0-190) B: CDAI fell 82 (IQR 41-137)	NA
Jauregui-Amezaga et al[29]	21 evaluable	12 mo	1 after CMV infection and multiorganic failure	NA	NA

NA: Not available; CDAI: Crohn´s disease activity index; IQR: Interquartile range; CMV: Cytomegalovirus.

Table 2 Mesenchymal stem cell transplantation studies in luminal inflammatory bowel diseases

Ref.	Patient (n)	Procedence	Follow up (d, mo or wk)	SAEs	Response/remission (number of patients, time of evaluation)	Recurrence (number of patients, time of evaluation)
Onken et al[45]	10 CD (9 evaluable)	BM	28 d	No SAES	Clinical	NA
		Allogenic			3/1 (28 d)
Duijvestein et al[46]	10 CD (9 evaluable)	BM	14 wk	No SAEs	Clinical	NA
		Autologous			3/0 (6 wk)
					Endoscopic
					0/2 (6 wk)
Liang et al[47]	7 (4 CD/3UC)	BM/umbilical cord	19 mo (range 6-32)	No SAEs	Clinical	1-3
		Allogenic			7/3 (12 wk)
					Endoscopic
					3/0 (3-5 mo)
Osiris Therap-eutics[48]	Estimated 330 CD	BM	NA	NA	NA	NA
		Allogenic
Forbes et al[49]	16 CD (15 evaluable)	BM	42 d	1 SAE probably not related	Clinical	NA
		Allogenic			12/8 (42 d)
					Endoscopic
					7/0 (42 d)
Lazebnik et al[50]	39 UC 11 CD	BM	4-8 mo	NA	Clinical response	NA
		Allogenic			UC 39/39
					CD 11/11

BM: Bone marrow; SAEs: Serious adverse events; NA: Not available; CD: Crohn´s disease; UC: Ulcerative colitis.

Table 3 Mesenchymal stem cell transplantation studies in perianal Crohn's disease

Ref.	Patients (n)	Procedence	Follow up (mo)	SAEs related	Response/closure (number of patients or fistulas, time of evaluation	Recurrence (number of patients, time of evaluation in months)
García-Olmo et al[53]	4 patients (8 fistulas)	Adipose Autologous	22 mo (range 12-30)	No	2/6 (2 mo)	NA
García-Olmo et al[54]	49 (14 CD) 25 (7 CD) fibrin glue (group A) 24 (7CD) ASCs (group B)	Adipose Autologous	12 mo	No	Group A: NA/1 (7 CD) Group B: 2/5 (7 CD)	3/17 global recurrence in group B (12 mo) Data for CD NA
Ciccocioppo et al[55]	10	BM Autologous	12 mo	No	3/7 (12 mo)	0/7 (12 mo)
de la Portilla et al[56]	22 per protocol	Adipose Allogenic	6 mo	2 SAEs possibly related Pyerxia Abscess	Closure: 5/18 fistulas (6 mo)	NA
Cho et al[57]	10	Adipose Autologous	6 mo	No SAEs	1/3 (2 mo)	0/3 (8 mo)
Lee et al[58]	33 per protocol	Adipose Autologous	12 mo	No SAEs	5/27 (2 mo) Per protocol	3/26 (12 mo)

BM: Bone marrow; CD: Crohn´s disease; NA: Not available.